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Abstract
Introduction Patients with unknown stroke onset are gener-
ally excluded from acute recanalisation treatments. We
designed a pilot study to assess feasibility of a trial of
perfusion computed tomography (PCT)-guided thrombolysis
in patients with ischemic tissue at risk of infarction and
unknown stroke onset.
Methods Patients with a supratentorial stroke of unknown
onset in the middle cerebral artery territory and significant
volume of at-risk tissue on PCT were randomized to
intravenous thrombolysis with alteplase (0.9 mg/kg) or
placebo. Feasibility endpoints were randomization and
blinded treatment of patients within 2 h after hospital
arrival, and the correct application (estimation) of the
perfusion imaging criteria.
Results At baseline, there was a trend towards older age
[69.5 (57–78) vs. 49 (44–78)years] in the thrombolysis
group (n=6) compared to placebo (n=6). Regarding
feasibility, hospital arrival to treatment delay was above
the allowed 2 h in three patients (25%). There were two
protocol violations (17%) regarding PCT, both underesti-
mating the predicted infarct in patients randomized in the
placebo group. No symptomatic hemorrhage or death
occurred during the first 7 days. Three of the four (75%)
and one of the five (20%) patients were recanalized in the
thrombolysis and placebo group respectively. The volume
of non-infarcted at-risk tissue was 84 (44–206)cm3 in the
treatment arm and 29 (8–105)cm3 in the placebo arm.
Conclusions This pilot study shows that a randomized PCT-
guided thrombolysis trial in patients with stroke of
unknown onset may be feasible if issues such as treatment
delays and reliable identification of tissue at risk of
infarction tissue are resolved. Safety and efficiency of such
an approach need to be established.
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The implementation of intravenous thrombolysis with recom-
binant tissue plasminogen activator (rTPA) in the late 1990s
after the results of the National Institute of Neurological
Disorders and Stroke rtPA Stroke trial [1] was a cornerstone
in the acute management of ischemic stroke. The results of
the European Cooperative Acute Stroke Study (ECASS) III
[2] and the Prolyse in Acute Cerebral Thromboembolism II
trial (PROACT II) [3] may allow for a longer time window
for acute recanalisation if approved by authorities, although
the publication of these studies has already lead to a rapid
and lasting increase of thrombolysis in acute stroke patients
[4]. The reasons why a majority of patients do not receive
thrombolytic treatment are late hospital arrival and unknown
time of stroke onset. For example, 33.1% of all stroke
patients admitted to our institution between 2003 and 2008
were of unknown onset, with the typical case being wake-up
strokes or aphasic patients who suffered a stroke without any
witness [5]. The only trial specifically aimed at treating
wake-up stroke patients has, based on standard neuro-
imaging, produced negative results [6].
Modern imaging like perfusion computed tomography
(PCT) and diffusion and perfusion-weighted magnetic
resonance (DWI-PWI-MRI) have been investigated for
prediction of tissue infarction. On MRI for example, final
infarct can be predicted with rather good accuracy with acute
DWI [7], and with very high accuracy with subacute fluid-
attenuated inversion recovery [8]. Properly executed PCT is
well tolerated, readily available, and is currently performed
in many centers as part of a standard CT protocol, which
also includes non-contrast CT and CT angiography [9].
Although it requires further validation [10], systematic
evaluations of thresholds have been performed to predict
tissue infarction and identify at-risk ischemic brain [11, 12].
Up to now, all mismatch-based thrombolysis trials set an
upper threshold for the onset-to-intervention interval, which
ranged from 6 h [13, 14] to 9 h [15–17]. On the contrary, no
randomized trial has yet been performed in unknown-onset
stroke patients, although a at-risk tissue may still persist up
to 18 h in 44.1% of patients [18] and in 37.1% of wake-up
patients [19].
Themain aim of this pilot study was to assess the feasibility
of performing a randomized PCT-guided thrombolysis trial in
patients with a limited volume of predicted tissue infarct,
significant volumes of tissue at risk of infarction, and
unknown stroke onset.
Methods
This was a single-center, prospective, randomized, double-
blinded, placebo-controlled, phase II study to investigate
the feasibility of r-TPA administration in patients with acute
ischemic stroke of unknown onset and a large volume of at-
risk brain tissue assessed by PCT. The study was approved
by the hospital ethics committee. Signed informed consent
was obtained from all patients or a proxy if the patient
could not be consented. This study was not registered in
http://www.clinicaltrials.gov because it was initiated before
2005 (when the registration of randomized controlled trials
became mandatory). This report was written in accordance
with the CONSORT reporting guidelines [20, 21].
Study population
Patients with a supratentorial stroke including the territory
of the middle cerebral artery were eligible for the study.
Stroke onset was considered “unknown” when the exact
time of stroke onset was estimated with more than 1 h
uncertainty. Furthermore, hospital arrival had to be too late
for standard IV thrombolysis within 3 h since last proof of
good health, which was the time limit recommended by
professional societies and accepted by national authorities
during the study period. Finally, last proof of well-being
had to be not more than 24 h. The other inclusion and
exclusion criteria are presented in Table 1. Based on
expected low chance of finding patient fulfilling all
inclusion/exclusion criterion in a single center, and the
pilot character of the study, we aimed at recruiting 12
patients over a 2-year period. All clinical outcomes were
assessed by National Institute of Health Stroke Scale score
(NIHSS)- and Rankin-certified stroke neurologists.
Imaging protocol
CT, PCT, and CTA were performed on a General Electrics
Lightspeed 16 advantage (16 detectors; General Electric
Company, Fairfield, CT, USA) until November 2005, and a
General Electrics Lightspeed VCT (64 detectors) thereafter,
using their commercially available software. For the PCT,
acquisition delay was 7 s after injection of 50 ml of iohexol
(300 mg/ml of iodine; Accupaque 300, Amersham, Oslo,
Norway) with a rate of injection of 5 ml per second into an
antecubital vein using a power injector (Stellant® DCT
Injection System; Medrad, Warrendale, PA, USA). Two
injections with acquisition of two 10-mm slices each were
acquired. The PCT data were transferred to a workstation
and analyzed using perfusion analysis software to create
parametric maps of mean transit time (MTT), cerebral
blood flow (CBF), and cerebral blood volume (CBV) map
utilizing a deconvolution software developed by Philips
Medical Systems (Cleveland, OH, USA). The CTP-
predicted infarct and at-risk ischemic tissue were semi-
automatically calculated by the software using the appro-
priate MTT and CBV thresholds (MTT>145% of the
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contralateral side values and CBV<2.0 mL/100 g to define
PCT-predicted infarct core; MTT>145% of the contralateral
side values and CBV>2.0 mL/100 g to define at-risk
ischemic tissue) [11]. These thresholds, although expressed
partially as absolute values, are relative values and depend
on the acquisition and calculation software. These recon-
structions require the radiologist to assess the quality of
input and output function and to select cerebral arteries and
veins for the deconvolution process
In the acute situation, reconstruction of PCT was
performed by the on-call radiologist in training, and a
visual estimation of predicted infarct and at-risk ischemic
tissue was performed after semi-automated reconstruction
by a stroke neurologist (PM) and the same radiologist. For
the final analysis, images were reconstructed by an
experienced neuroradiologist (MW). In addition to
measuring the volume of the predicted infarct and of
the tissue at risk using the computer software, he
compared the ischemic volumes (predicted infarct and
tissue at risk) with the entire MCA territory of the
individual patient and expressed this as percentages. For
this, 100% of the MCA territory was determined for each
patient using estimated borders of the territory.
CTA was performed immediately before or after CTP;
results of CTA were not used as an inclusion/exclusion
criterion.
Selection criteria based on perfusion CT
We used systemically evaluated thresholds to generate PCT
images, which allow approximate prediction of infarct and
of tissue at risk [11]. It has been shown that the benefit of
thrombolysis (a) is reciprocally associated with the extent
of the initially predicted infarct volume and becomes
unfavorable when this exceeds 30–40% of the territory of
the middle cerebral artery (MCA) [22, 23] and (b) increases
with a high ratio of tissue at risk/predicted infarct [13, 14].
Based on these findings, we set an upper limit for the extent
of predicted infarction, which should not exceed 30% of the
MCA territory. In addition, we set a variable threshold for
the extent of the at-risk brain tissue as shown in Fig. 1,
where stroke index is defined as at-risk tissue/( at-risk
tissue+predicted infarct): With little predicted infarct and
relatively small at-risk tissue, thrombolysis was considered
worth-performing and safe, whereas in case of a larger
predicted infarct, the patient should have more at-risk tissue
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Informed consent Epileptic seizure at stroke onset
Unknown stroke onset Presentation with coma
Age 18–80 years Rapid clinical improvement or minor stroke (NIHSS, <6)
NIHSS 6–22 at the start of treatment Symptoms or signs suggestive of a subarachnoid hemorrhage
Hemispheric stroke syndrome SBP>185 or DBP>110, which does not respond to 10 mg i.v. labetalol
Pre-stroke modified Rankin score=0–1 and Barthel index≥95 Hypo- (<2.7 mmol/l) or hyperglycemia (>22.2 mmol/l)
CT-to-treatment interval (<60 min) Thrombocytopenia <100,000/μl
Favourable PCT profile (Fig. 1) International normalized ratio>1.5
Activated partial thrombin time>33 s
Pregnancy, terminal illness
Known allergy to iodine
Metformin <24 h before contrast injection
Creatinine>150 mmol/l (unless on chronic dialysis)
History of intracranial hemorrhage
Recent stroke or traumatic brain injury (<3 months)
Recent traumatic cardiac massage (<10 days)
Recent arterial puncture at a non-compressible site (<7 days)
Recent gastrointestinal bleeding or hematuria (<21 days)
Recent major surgery (<14 days)
Substantial occlusion of the extracranial internal carotid artery
Intracranial hemorrhage in NCCT
Suspicion of aneurysm or intracranial vascular malformation in NCCT and CTA
NIHSS National Institute of Health Stroke Scale score, CT computed tomography, NCCT non-contrast CT, CTA CT angiography, SBP/DBP
systolic/diastolic blood pressure, PCT perfusion CT
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to be treated. This concept was chosen to limit the risk of
bleeding and increase the chances of a treatment response.
Treatment protocol
The rTPA (Actilyse® Boehringer Ingelheim GmbH, Ger-
many) was administered intravenously at a dose of 0.9 mg/
kg of body weight (maximum of 90 mg), with 10% of the
dose as a bolus infusion and the rest 90% as an hourly
infusion. Placebo consisted of lyophilized powder produced
in the hospital’s pharmacy. Both regimens (rTPA and
placebo) were placed in identical bottles by the hospital
pharmacy and were indistinguishable in appearance. The
general management of patients followed international
guidelines valid during the study period [24].
Randomization and allocation to treatment
Randomization was performed on a 1:1 basis according to a
random number table generated by an independent hospital
pharmacist who was not involved in patient management and
outcome assessment. Enrollment of patients and allocation to
treatment was performed by blinded treating physicians. All
medical personnel involved in the study were blinded during
treatment and outcome assessment, except for the pharmacy.
Unblinding was performed by the hospital pharmacy after all
patients had completed their follow-up of 3 months.
Primary outcome
The main aim of the study was feasibility, as measured by
(a) delay from hospital arrival to treatment≤2 h and (b) the
correct application of the PCT-inclusion criteria (details see
below) in all patients. The rather long arrival-to-treatment
delay was chosen because it included acquisition and
interpretation of perfusion imaging, informed consent, and
the randomization process.
Secondary outcomes
Secondary endpoints included symptomatic and asymp-
tomatic intracerebral hemorrhage at 24 h and 4 days after
treatment (assessed by CT or MRI respectively) according
to the ECASS II criteria [22] and mortality at 7 and
90 days.
We also assessed the volume of at-risk brain tissue on
PCT, which survived as compared to the T2W MRI lesion
at day 4, complete recanalisation (defined as no or <50%
narrowing on the control CTA at 24 h in all initially
occluded arteries), neurological outcome (NIHSS) at 1, 7,
and 90 days, and dependency (modified Rankin score and
Barthel index) at 90 days.
Monitoring
Patients were monitored closely in the intermediate care
stroke unit for clinical worsening and complications and
appropriate examinations were performed if this occurred.
At 24 h, repeat non-contrast CT with circle of Willis CT
angiography was performed in all patients, and at 4 days,
cerebral MRI with MR angiography was obtained in all
patients. An interruption of the study was pre-planned if
more than three patients suffered symptomatic hemorrhage.
In such case, the pharmacy department would have broken
Fig. 1 Patients were eligible for
inclusion in the study if the
values of predicted infarct size
and stroke index were in the
green area. On the contrary,
values at the red area lead to
exclusion from the study be-
cause thrombolysis in these sit-
uations was considered to be
potentially unsafe. Stroke index:
at-risk tissue/(at-risk tissue+
predicted infarct). MCA Middle
cerebral artery. Asterisk and plus
symbol correspond to patients
randomized to placebo and rTPA
respectively
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the randomization code of the already enrolled patients and
informed two board-certified neurologists not participating in
the study so that they could evaluate whether symptomatic
hemorrhage (or death) was attributable to rtPA and whether
the study should be terminated.
Statistical analysis
Analysis was performed on an intention-to-treat basis.
Continuous variables are reported as median (range). Com-
parisons were performed by Fisher’s exact test for categorical
variables and Wilcoxon test for continuous variables. The
level of significance was set at 95% (p=0.05). The statistical
analysis was performed with Stata Statistical Software
(Release 10. College Station, TX, USA: StataCorp LP 2007).
Results
Of the 1090 consecutive patients with an acute (<24 h after
symptom onset) ischemic stroke admitted to the stroke unit
or intensive care of our institution between 06/2004 and 12/
2007 (3.5 years), 12 patients were randomized to rTPA or
placebo (Fig. 2). Of the randomized patients, nine (75%)
suffered a wake-up stroke (four in the rTPA group and five
in the placebo group). The others were strokes with
Assessed for eligibility (n=1090)
Excluded (n=1078)
Known onset (n=802)
Onset-to-admission interval <150 minutes (n=434)
Age >80 years (n=288)
Previously dependent* (n=208)
NIHSS at admission: <6 (n=499) or >22 (n=85)
Non-MCA territory (n=435)
Recent (<90 days) ischemic stroke (n=46)
Bleeding risk (n=95)
Previous intracranial haemorrhage (n=9)
Intracranial aneurysm/vascular malformation (n=11)
Known/suspected allergy to contrast (n=11)
Renal causes (n=89)
PCT uninterpretable (n=29) or not performed (n=349)
Unfavourable PCT profile (n=11)
Declined to participate (n=3)
Analysed (n=6)
Lost to follow-up (n=0)
Allocated to intervention (n=6)
Received allocated intervention (n=6)
Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Allocated to intervention (n=6)
Received allocated intervention (n=6)







Fig. 2 Study flow diagram. Patients may have had multiple reasons
for not being eligible for the trial. NIHSS National Institute of Health
Stroke Scale score,MCA middle cerebral artery, LMWH low molecular
weight heparin, INR international normalized ratio, PCT perfusion CT,
MRI magnetic resonance imaging, rTPA recombinant tissue plasmin-
ogen activator. Asterisk Previous modified Rankin score ≤2
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unknown onset with last proof of well-being during
daytime. The ischemic lesion affected the right hemisphere
in four patients in the placebo group and two in the active
treatment arm. There were no significant differences in
gender, NIHSS at admission, and time interval between last
proof of well-being and onset of treatment between the
active treatment and the placebo groups. However, there
was a trend towards older age and higher NIHSS in the
active treatment arm and to higher predicted infarct
volumes in the placebo group (Table 2).
Door-to-needle time was a median of 113 (75–205)min,
and three patients received treatment or placebo beyond the
goal of 2 h: two patients in the placebo group (at 138 and
205 min.) and one in the rtPA group (131 min).
Reanalysis of PCT data after the end of the study
showed protocol violations in two patients, both in the
placebo arm. They were randomized based on favorable
appearing perfusion profiles in the emergency room. The
reanalyzed predicted infarct volumes of these two patients
in fact exceeded the threshold described in Fig. 1 and were
beyond 30% of the MCA territory
No patients were lost to follow-up. Regarding safety,
there was no symptomatic intracranial hemorrhage or death
during the first 7 days after randomization, and there were
five asymptomatic hemorrhagic transformations at 4 days
(three in the rTPA group and two in the placebo group). The
volume of noninfarcted at-risk tissue and recanalization
rates were higher in the active treatment arm. Neurological
and clinical outcome in patients treated with rTPA was not
worse compared to placebo patients (Table 3). Figure 3
presents an example of a patient who was randomized to,
and has received rt-PA, with subsequent recanalisation and
favorable outcome.
Discussion
This pilot study shows that a randomized PCT-guided
thrombolysis trial in patients with stroke of unknown onset
is partially feasible. Difficulties included protocol violations
regarding door-to-needle time in 25% of patients and in
respecting the prespecified perfusion-imaging criteria in
16.7% of patients.
Adding perfusion and arterial imaging criteria to decisions
on treatment strategy is likely to increase the delay to
treatment initiation. Given the importance of time in
traditional thrombolysis protocols [25], such additional
imaging needs to be shown feasible and of additive value
[26, 27]. Our median door-to-needle time of 113 (75–205)
min may be partially explained by the need for reconstruc-
tion of PCT threshold maps, signed informed consent, and
randomization procedures. It may show limits of the
feasibility of such a thrombolysis protocol and should clearly
be reduced in future trials. Secondly, the fact that initial
calculations of PCT volumes performed at the emergency
room were imprecise in two out of 12 patients (and hence,
lead to an incorrect inclusion) is of concern and needs to be
improved. Although this rate is similar to the rate of protocol
violations of the non-contrast CT based “1/3 MCA territory
rule” observed in another, large thrombolysis trial [23], the
recent CT-based ECASS-3 trial had a low rate of radiological
protocol violations of only 2.1% [2]. Thirdly, the recruitment
period had to be enlarged from the planned 2–3.5 years to
recruit the 12 patients in a single center, hinting at a rather
restricted number of eligible and patients for such a trial.
A recent combined analysis of randomized thrombolysis
trials found no convincing evidence to support that the risk
of serious or fatal symptomatic hemorrhage increases with
late initiation of thrombolysis [25]. In this sense, the main
argument against late administration of rTPA in stroke
patients would be the potential lack of efficacy, which could
be due to lack of at-risk tissue or more resistance to
recanalizing occluded arteries. Hypothetically, the demon-
stration of at-risk tissue may be as important as time in order
to identify responders to acute recanalisation treatments.
This concept seems to be supported by data from patients
treated within 6 h who underwent perfusion imaging before
thrombolysis [13, 14].
We also restricted our study to patients with small
volumes of predicted infarct, which may allow limiting the
hemorrhage risk [28]. Indeed, no symptomatic hemorrhage
or death occurred in our study during the first 7 days after
rTPA administration, but our number of patients treated is too
small to assume safety with this protocol. When assessing
recanalisation, growth from predicted to final infarct and
survival of at-risk tissue as a potential surrogate marker for
efficacy of thrombolysis, we found no signs of adverse effects.
The only randomized controlled perfusion-imaging-
based thrombolysis study so far did not show a benefit in
a late-time window [17]. The employment in the present
study of a variable threshold incorporating not only the
relative size of at-risk tissue but also the initial infarct size
prediction may have lead to a more optimal selection of
patients. Although a combination of non-contrast CT, CTA
source imaging, and assessment of collaterals may be an
alternative strategy for identifying patients with particular
benefits of risk of (late) recanalisation, the advantage of
using semi-automated threshold-based CTP reconstructions
is that quantification of infarct prediction and at-risk tissue
becomes less operator dependent because there it is (a) less
subject to subjective visual estimations and (b) has
predefined thresholds, which have been identified by
systematic analysis of CTP generated values [11, 12]. On
the other hand, using sophisticated perfusion imaging
criteria for patient selection may severely limits the pool
of patients that are eligible for treatment.
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Patient characteristics rTPA group (n=6) Placebo group (n=6)
Demographics, time intervals
Age (years) 69.5 (57–78) 49 (44–78)
Female gender 3 (50.0%) 3 (50.0%)
Prehospital modified Rankin score=0 6 (100%) 5 (83.3%)
LPW-to-treatment time (minutes) 564 (390–805) 437.5 (330–656)
Admission-to-treatment time (minutes) 109.5 (85–131) 113 (75–205)
Wake-up strokes 4 (66.7%) 5 (83.3%)
Vital signs
Temperature (°C) 36.0 (34.2–37.0) 35.4 (34.4–36.1)
Systolic blood pressure (mmHg) 153 (109–200) 134 (100–196)
Diastolic blood pressure (mmHg) 83 (70–98) 81.5 (65–92)
Heart rate (min−1) 67 (62–109) 67 (50–92)
Laboratory values
Serum creatinine (μmol/l) 89 (66–104) 81 (68–99)
Glucose (mmol/l) 6.4 (5.7–16.8) 7.0 (5.5–9.6)
Total cholesterol (mmol/l) 4.6 (3.8–7.4) 6.2 (4.5–6.8)
White blood cell count (103/mm3) 9.5 (5.4–12.7) 10.0 (4.2–13.1)
Neuroimaging studies
Initially predicted infarct (cm3) 12.0 (1.1–26.2) 42.0 (11.4–179.4)
Initial at-risk tissue 90.3 (30.5–207.8) 75.8 (60.4–114.6)
Arterial imaging on admission
MCA segment 1 or 2 occlusion 5 (50%) 4 (67%)
Extracranial carotid occlusion 4 (67%) 1 (17%)
Clinical examination
NIHSS at admission 17 (13–21) 14.5 (12–19)
NIHSS at 4–6 h 13 (8–19) 18 (11–23)
NIHSS at 24 h 10.5 (7–19) 19.5 (6–24)
Risk factors and medical history
Hypertension 4 (66.7%) 1 (16.7%)
Atrial fibrillation 2 (33.3%) –
Dyslipidemia 4 (66.7%) 3 (50.0%)
Diabetes mellitus 1 (16.7%) –
Mechanical or biological valve – –
Coronary artery – –
Active smoking – 2 (33.3%)
Periphery artery disease – –
Previous treatment
Antiplatelet treatment 2 (33.3%) 1 (16.7%)
Anticoagulant – –
Antihypertensives 3 (50.0%) 1 (16.7%)
Oral hypoglycemic agents – 1 (16.7%)
Insulin – –
Lipid-lowering drugs 2 (33.3%) –
Stroke subtypes
Atherosclerotic 2 (33.3%) –
Cardioembolic 2 (33.3%) –
Dissection – 4 (66.7%)
Undetermined 2 (33.3%) 2 (33.3%)
Table 2 Baseline characteristics
Data are medians (range) for
continuous variables and counts
(%) for categorical
rTPA recombinant tissue plas-
minogen activator, LPW last
proof of well-being, NIHSS
National Institute of Health
Stroke Scale score
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The results of the present study are limited by its small
sample size, leading to a major inequalities in baseline
variables, limited amount of information regarding feasi-
bility, and insufficient power to study safety, biological
efficacy (such as recanalisation or growth of predicted to
final infarct), and clinical efficiency. Higher age, higher
Table 3 Rates of hemorrhagic transformation and mortality and indices of radiological and clinical outcome
Outcome rTPA group (n=6) Placebo group (n=6)
Symptomatic hemorrhagic transformation at 24 h/4 days 0/0 0/0
Asymptomatic hemorrhagic transformations at 24 h (CT) 2 2
Asymptomatic hemorrhagic transformations at 4 days (MRI) 3 2
Mortality at 7/90 days 0/0 0/0
Recanalization 3/4c (75%) 1/5c (20%)
Non-infarcted at-risk tissue (cm3)a 84 (44–206) 29 (8–105)
NIHSSb 4 (0–6) 9.5 (6–15)
Barthel indexb 95 (30–95) 70 (80–100)
Modified Rankin scoreb 1.5 (1–5) 3.0 (2–4)
Favorable functional outcome (Modified Rankin score ≤2)b 4/6 (66.6%) 1/6 (16.6%)
For recanalization, non-infarted at-risk tissue, NIHSS Barthel index, and modified Rankin score: numbers represent median values (range)
rTPA Recombinant tissue plasminogen activator, NIHSS National Institute of Health Stroke Scale score
a Defined as the volume of at-risk tissue on PCT surviving as compared to the T2W MRI lesion at day 4
b Assessed at 3 months
c The denominator refers to patients with arterial occlusion diagnosed at admission
Fig. 3 Example from a 75-year-
old man with a wake-up stroke
with aphasia and right hemisyn-
drome, NIHSS=21. Admission
perfusion CT (a) performed 8 h
30 min after going to bed. Pre-
dicted infarct of 14.1 cm3 (red)
and at-risk tissue of 207.8 cm3
(green) in the territory of the left
middle cerebral artery due to an
occlusion of the left MCA main
stem (CTA, b). Randomized to
intravenous thrombolysis, study
drug started 9 h 5 min after last
proof of well-being. Complete
recanalisation was diagnosed at
24 h CTA (d) with a final infarct
volume of 15.7 cm3 (5-day DWI-
MRI, c). At 3 months, modified
Rankin score of 1 and Barthel
index of 100
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NIHSS, and lower predicted infarct in the rtPA group have
potentially opposing influences on radiological and clinical
outcomes, but again, numbers are too small for any
meaningful adjustments or conclusions regarding efficacy.
Secondly, systematic evaluation of infarct prediction by
CTP has yielded different predictive threshold models
based either on a combination of relative MTT and CBV
[11] or on a relative CBF threshold [12]. Finally, arterial
imaging was performed but not used for the selection
process. This was done because (a) the presence of at-risk
tissue on CTP despite the absence of large arterial occlusion
may indicate thrombolysable distal vessel occlusion and (b)
perfusion imaging is commonly regarded as the technically
more challenging part in multimodal acute stroke imaging
if compared with acute arterial imaging. Retrospective
analysis of the DIAS-2 trial suggests that acute arterial
occlusion may better identify thrombolysis responders than
mismatch on perfusion imaging [17].
In summary, this pilot study shows that a PCT-guided
randomized thrombolysis trial in patients with stroke of
unknown onset may be feasible if issues such as delay
from hospital arrival to treatment can be resolved and if
early infarct prediction by perfusion imaging can be
obtained reliably and accurately. Before starting a random-
ized trial with clinical efficiency as a primary outcome,
additional safety and biological efficacy data should be
obtained. Such a clinical efficiency trial would then require
357 patients to detect an absolute difference of 15% in
favorable outcome (modified Rankin score, ≤2) with a
power of 80% and a two-sided α error of 5%, assuming a
rate of 55% favorable outcome in the thrombolysis arm
[29] and a dropout rate of 5%.
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